CARLSBAD, Calif., July 11, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ:LIFE - News) today announced that it will accelerate development of its Ion Torrent Semiconductor technology for a broad set of proteomic and antibody-based applications after passing internal Life Technologies R&D milestones.
Proteomic and antibody-based technologies are used prevalently across multiple addressable markets in research, applied sciences and clinical diagnostics. Research and development teams across Life Technologies are focused on new product development in these addressable markets.
Life Technologies anticipates potential initial applications in transplant diagnostics (human leukocyte antigen - HLA), microbiology, and food safety testing, but additional application areas may be explored internally or via partnership.
"Our internal efforts are accelerating the research and development to build products which use Ion Torrent to detect signals inherent in the binding complexes with proteins, antigens and antibodies," said Alan Sachs, chief scientific officer of Life Technologies.
Life Technologies is committed to continuing to invest in the development of these proteomic and antibody-based applications for the Ion Torrent technology and in expanding its intellectual property portfolio in this arena.
Antibody / antigen complexes and proteins can be combined with bead-based sample-preparation technologies used on Ion Torrent's Semiconductor Sequencing technologies. The sensitive signal detection available on the Ion Torrent semiconductor chip works by recognizing electrical and ionic changes through a sensor, and the currently available products are being used with nucleic acids.
"In disease areas like Transplant Diagnostics and Cancer, having the ability to analyze proteins and genes on the same system, in the same lab, brings convenience, better turnaround time and allows for democratization of critical information for better patient management," said Ronnie Andrews, president of Medical Sciences at Life Technologies.
The Ion PGM system is currently for research purposes only and is not intended for diagnostic uses.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent, Applied Biosystems®, Invitrogen, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website: http://www.lifetechnologies.com.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact
SOURCE Life Technologies